{"response": {"meta": {"time": 18, "hits": 2, "offset": 0}, "docs": [{"news_desk": null, "document_type": "article", "_id": "4fd1cc0a8eb7c8105d701ffc", "headline": {"main": "A Fat Drug: Hopes and Reality"}, "pub_date": "1993-07-14T00:00:00Z", "slideshow_credits": null, "source": "The New York Times", "byline": {"original": "By NATALIE ANGIER", "person": [{"lastname": "ANGIER", "rank": 1, "firstname": "Natalie", "organization": "", "role": "reported"}]}, "abstract": null, "web_url": "http://www.nytimes.com/1993/07/14/health/a-fat-drug-hopes-and-reality.html", "section_name": "Health", "lead_paragraph": "A NOVEL type of diet drug has entered the final stretch of clinical testing in the United States and Europe, and, as might be expected with any new strategy on the weight-control front, rumors about its prowess have been greatly exaggerated. The new medication, called either by its chemical name, tetrahydrolipstatin, or by its generic name, orlistat, works in what seems to be the sweetest possible fashion, blocking the absorption of much of the fat that has been consumed and allowing it to pass right through the intestines before the body's annoyingly efficient storage system has a chance to claim it as its own. In so doing, the drug can help eliminate about 10 to 15 percent of the day's caloric intake with relative ease, sort of allowing dieters to eat their cake and not have it, too.", "snippet": "A NOVEL type of diet drug has entered the final stretch of clinical testing in the United States and Europe, and, as might be expected with any new strategy on the weight-control front, rumors about its prowess have been greatly exaggerated.   The...", "blog": [], "keywords": [{"value": "HOFFMANN-LA ROCHE INC", "name": "organizations"}, {"value": "WEIGHT", "name": "subject"}, {"value": "ORLISTAT (DRUG)", "name": "subject"}, {"value": "DIETING", "name": "subject"}, {"value": "DRUGS (PHARMACEUTICALS)", "name": "subject"}, {"value": "EXERCISE", "name": "subject"}, {"value": "OILS AND FATS", "name": "subject"}, {"value": "TESTS AND TESTING", "name": "subject"}, {"value": "NEW MODELS, DESIGN AND PRODUCTS", "name": "subject"}, {"value": "TETRAHYDROLIPSTATIN (DRUG)", "name": "subject"}], "print_page": "1", "type_of_material": "News", "word_count": 1240, "subsection_name": null, "multimedia": []}, {"news_desk": "Obituary", "document_type": "article", "_id": "4fd1a9a48eb7c8105d6c6d52", "headline": {"main": "Mark L. Morris, 92, A Developer of Diets For Cats and Dogs"}, "pub_date": "1993-07-13T00:00:00Z", "slideshow_credits": null, "source": "The New York Times", "byline": {"original": "By MARVINE HOWE", "person": [{"lastname": "HOWE", "rank": 1, "firstname": "Marvine", "organization": "", "role": "reported"}]}, "abstract": null, "web_url": "http://www.nytimes.com/1993/07/13/obituaries/mark-l-morris-92-a-developer-of-diets-for-cats-and-dogs.html", "section_name": "Obituaries", "lead_paragraph": "Dr. Mark Loren Morris, a pioneer in animal health who developed diets for dogs and cats, died on Thursday at his home in Naples, Fla. He was 92. The cause was atherosclerosis, a disease of the arteries, the family said.", "snippet": "Dr. Mark Loren Morris, a pioneer in animal health who developed diets for dogs and cats, died on Thursday at his home in Naples, Fla. He was 92.   The cause was atherosclerosis, a disease of the arteries, the family said.", "blog": [], "keywords": [{"value": "MORRIS, MARK LOREN", "name": "persons"}, {"value": "BIOGRAPHICAL INFORMATION", "name": "subject"}, {"value": "DEATHS", "name": "subject"}], "print_page": "7", "type_of_material": "Obituary; Biography", "word_count": 304, "subsection_name": null, "multimedia": []}]}, "status": "OK", "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}